Ultraman Expands Blood Vision Across India, Introduces Vision Cloud for Personalized Health Insights

Ultraman today announced that it is expanding its blood vision service to more than 60 cities and 2,000+ pin codes. The expansion aims to provide affordable access to the company’s premium preventive health services to millions of customers. The company has also launched Vision Cloud, which it claims is the world’s first free universal health interpreter, and allows users to upload past blood test results and get personalized insights in the Ultraman app.

Through a partnership with Tata 1mg, Ultraman Blood Vision will offer in-home sample collection by trained phlebotomists. BloodVision offers 15 curated test panels, starting at $99,999. The base plan ($1,999) includes more than 60 essential biomarkers, while the premium plan includes 100+ advanced markers in cardiovascular, metabolic, hormonal, and longevity pathways.

Blood vision

Blood Vision results are delivered directly within the Ultraman app, eliminating the need for PDFs. Each marker is accompanied by reference ranges and actionable insights, enhanced by the company’s UltraTrace technology that integrates lifestyle data from Ultraman Ring Air. This data helps users track their well-being across multiple factors, including sleep, mobility, and recovery, and provides personalized health recommendations based on their results.

Ultrawoman’s new Vision Cloud feature supports users by offering free, AI-powered interpretation of past blood test reports. The tool offers a personalized health analysis, including supplement recommendations and BloodAge scores. Vision Cloud will expand in the future to interpret additional diagnostic data, including microbiome, cancer, CT scans, and MRI, with the goal of building a fully integrated health ecosystem for users globally.

The expansion into India marks a major milestone in Ultrawoman’s global strategy, which already includes operations in Saudi Arabia and the United Arab Emirates, with future launches planned for the UK and Australia. The company also plans to expand its interpretation capabilities to include genetics, microbiome data, and lifestyle risk profiling in the near future.